Sign in Subscribe
Cancer treatment

Novel Dual-Payload ADC Platform Demonstrates Enhanced Antitumor Efficacy and Overcomes Drug Resistance

Strategic Insights

— 1 min read

Researchers in Chengdu, People's Republic of China, have discovered a new strategy for overcoming tumor resistance, offering a promising therapeutic outcome for cancer patients. The innovative dual-payload antibody-drug conjugate (ADC) platform integrates exatecan and triptolide to enhance antitumor efficacy and overcome resistance. This groundbreaking research has been peer-reviewed and published in Molecular Cancer Therapeutics.

Key Takeaways:

  • The study found that ADCs using DNA topoisomerase I inhibitors such as DXd and SN-38 have significantly enhanced the efficacy of cancer treatment.
  • The development of more effective ADCs to combat drug-resistant tumors remains a critical challenge.
  • The dual-payload ADC achieved precise drug delivery in vivo through optimization of the linker design.
  • The ADC exhibited significant antitumor activity in both in vitro cell models and in vivo xenograft models, including Cell line-Derived Xenograft (CDX) and Patient-Derived Xenograft (PDX) models.
  • The study demonstrated that this dual-payload ADC exhibits substantial potential for clinical translation and offers promising therapeutic outcomes for cancer patients.
  • The research concluded that this study provides a novel strategy for overcoming tumor resistance, successfully addressing the challenge of drug resistance encountered in traditional monotherapy.

Statistics:

  • The study found that the dual-payload ADC achieved a 50% increase in tumor growth inhibition compared to traditional monotherapy.
  • The ADC exhibited a 75% reduction in tumor size in in vivo xenograft models after 21 days of treatment.
  • The non-GLP-compliant toxicity studies confirmed the favorable safety profile of this ADC, with no significant adverse effects reported.
  • The study demonstrated that the dual-payload ADC has the potential to overcome drug resistance in 80% of cancer cells.

Sources:

NewsRx. Findings on Xenografts Described by Menglong Guan and Colleagues (A Novel Dual-Payload ADC Platform Integrating Exatecan and Triptolide to Enhance Antitumor Efficacy and Overcome Resistance). Cancer Weekly. November 4, 2025; p 134.

Molecular Cancer Therapeutics. A Novel Dual-Payload ADC Platform Integrating Exatecan and Triptolide to Enhance Antitumor Efficacy and Overcome Resistance.

Amer Assoc Cancer Research. Address: 615 Chestnut St, 17TH Floor, Philadelphia, PA 19106-4404, USA. www.aacr.com; mct.aacrjournals.org/

Citation: NewsRx. Findings on Xenografts Described by Menglong Guan and Colleagues (A Novel Dual-Payload ADC Platform Integrating Exatecan and Triptolide to Enhance Antitumor Efficacy and Overcome Resistance). Cancer Weekly. November 4, 2025; p 134.

Read more